Showing 828 results
-
Media Release /- Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Media Release /- Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
-
Media Release /- At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached- Grade 3/4…
-
Media Release /- ASLeap trial to evaluate impact of increasing the dose of Cosentyx (secukinumab) to 300 mg in patients who do not achieve symptom remission after 16 weeks of treatment with the approved dose of 150…
-
Media Release /- Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early…
-
Media Release /- Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal…
-
Media Release /- Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)- In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82%…
-
Media Release /- Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN…
-
Media Release /- US label updated to include Cosentyx® (secukinumab) data in moderate to severe scalp psoriasis - one of the difficult-to-treat types of psoriasis(1,2)- Approximately half of all 125 million…
-
Media Release /-- Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1)-- Data…
